Diametric Capital, LP Cyclerion Therapeutics, Inc. Transaction History

Diametric Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.58 - $18.2 $99 - $3,130	172 Added 0.07%	243,711 $210,000
Q2 2022 Aug 15, 2022	BUY	$0.47 - $1.29 $28,486 - $78,185	60,609 Added 33.13%	243,539 $134,000
Q1 2022 May 16, 2022	BUY	$0.96 - $1.78 $79,152 - $146,761	82,450 Added 82.06%	182,930 $203,000
Q4 2021 Feb 14, 2022	BUY	$1.56 - $2.99 $47,832 - $91,679	30,662 Added 43.92%	100,480 $173,000
Q3 2021 Nov 15, 2021	SELL	$2.73 - $4.13 $28,714 - $43,439	-10,518 Reduced 13.09%	69,818 $214,000
Q2 2021 Aug 16, 2021	BUY	$2.18 - $4.29 $175,132 - $344,641	80,336 New	80,336 $313,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $126M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Diametric Capital, LP with notifications on news.